• English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • français 
    • English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • Ouvrir une session
Voir le document 
  •   Accueil de DSpace
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • Voir le document
  •   Accueil de DSpace
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • Voir le document
JavaScript is disabled for your browser. Some features of this site may not work without it.
Tout DSpace
  • Communautés & Collections
  • Par date de publication
  • Auteurs
  • Titres
  • Sujets

Drug-Induced Nephrotoxicity in Inflammatory Bowel Disease

Thumbnail
Auteur
Oikonomou, K. A.; Kapsoritakis, A. N.; Stefanidis, I.; Potamianos, S. P.
Date
2011
DOI
10.1159/000326682
Sujet
Inflammatory bowel disease
Nephrotoxicity
Tubulointerstitial
nephritis
Glomerulonephritis
Aminosalicylates
Cyclosporine
Tumor
necrosis factor-alpha inhibitors
ANTI-TNF-ALPHA
INDUCED RENAL-FAILURE
CROHNS-DISEASE
INTERSTITIAL
NEPHRITIS
RHEUMATOID-ARTHRITIS
ULCERATIVE-COLITIS
NEPHROTIC-SYNDROME
5-AMINOSALICYLIC ACID
EXTRAINTESTINAL MANIFESTATION
TUBULOINTERSTITIAL
Urology & Nephrology
Afficher la notice complète
Résumé
Conservative management of inflammatory bowel disease (IBD) is based on a combination of drugs, including amino-salicylates (ASAs), steroids, antibiotics, immunosuppressives and biologic agents. Although various side effects have been related to treatment regimens, drug-induced nephrotoxicity is rather uncommon. Furthermore, it is often underestimated since renal function deterioration may be attributed to the underlying disease. The nephrotoxicity of ASAs and cyclosporine A seems well established, but recent data have suggested a possible role of biologic agents such as infliximab and adalimubab in renal impairment. The aim of this review is to summarize the nephrotoxic effects of medical treatment as well as to express possible caveats in the administration of novel agents in IBD. Copyright (C) 2011 S. Karger AG, Basel
URI
http://hdl.handle.net/11615/31477
Collections
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ. [19735]
htmlmap 

 

Parcourir

Tout DSpaceCommunautés & CollectionsPar date de publicationAuteursTitresSujetsCette collectionPar date de publicationAuteursTitresSujets

Mon compte

Ouvrir une sessionS'inscrire
Help Contact
DepositionAboutHelpContactez-nous
Choose LanguageTout DSpace
EnglishΕλληνικά
htmlmap